Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (March 2019)
15 slides from Alcidion's investor presentation, Mar 18, 2019
Slide 1: Investor Presentation: Enabling the transformation of healthcare
For personal use only Investor Presentation Enabling the transformation of healthcare Kate Quirke, Group Managing Director March 2019 1
Slide 2: The delivery of healthcare is changing
The delivery of healthcare is changing For personal use only More data doesn’t mean improved productivity or quality information for decision making: This is our opportunity • Increased spending on digital patient data has led to a decrease in productivity • Clinical risk and avoidable errors remain
Slide 3: The Alcidion business today
The Alcidion business today For personal use only Smart collection of clinical observations and UK: 12 customer patient data, clinical communication and AI driven contracts covering decision support systems 24 hospitals Fully integrated platform underpinned by leading edge, adaptable, platform techn
Slide 4: The Alcidion Difference
The Alcidion Difference • Big single solution EMR is not the answer For personal use only • care team productivity can drop by 20-30% • stifles innovation and hostage to one vendor solution • We have the platform to transform healthcare • Miya Precision is an innovative events driven platform • comb
Slide 5: Miya Precision
For personal use only Miya Precision Hospital Identify EMR, PAS Acquired deteriorating Complications patients and Clinical App & Critical clinical Smartpage Results documents Patientrack Labs, Radiology Specialty Complexity & Specific Views Patient Flow Coding EMR Integration Medications Orders Real
Slide 6: Clinical App
For personal use only Clinical App Smartpage Patientrack Specialty Specific Views, Integrated to EMR Real-Time Dashboards Hospital Operations
Slide 7: From this…To This
From this…………………………………..To This For personal use only 7
Slide 8: Market opportunity – AU, NZ, UK
Market opportunity – AU, NZ, UK For personal use only • International expansion initially Market adoption remains at an early stage with strong global growth drivers including need to eliminate focused where current customers preventable patient deaths and avoidable cardiac arrests exist - AU, NZ an
Slide 9: The Competitive Landscape
The Competitive Landscape For personal use only Category Usage How Alcidion compares / complements Major Players We help customers realise the value to these large, • Currently installed in most states of Australia EPIC transactional based systems through application of and in a number of NHS Trusts
Slide 10: An emerging leader in healthcare analytics
An emerging leader in healthcare analytics For personal use only Acquisitions First integrated Miya H1 FY19 revenue - $7.3M First UK contract Delivered positive completed MKM Patientrack announced for operational cash flow for Health/Patientrack Smartpage contract $14.8M revenue to be integrated Miy
Slide 11: H1 FY19 Highlights
H1 FY19 Highlights For personal use only Alcidion Group FY19 Contracted Revenue First half as the expanded Alcidion group delivers impressive Recurring vs Non-recurring (m) 16 contracted revenue growth and continued momentum FY19 Sold (Contracted) Revenue 14 12 • H1 FY2019 total revenue of $7.3 mill
Slide 12: Growth strategy
Growth strategy For personal use only Integration Cross-selling to existing customer base • Focus on key reference sites & established customers • Roles and products integrated • Grow pipeline • Brand consolidation project started • Speed up pipeline conversion • One Company from July 1 Technology e
Slide 13: Why invest in Alcidion
Why invest in Alcidion • Large market opportunity and the right context – digital patient data is For personal use only driving demand for better healthcare analytics • A leading-edge technology suite – increasingly looked upon as a strategic solution for improving healthcare delivery • Differentiat
Slide 14: Company snapshot
Company snapshot Capital Structure Major Shareholders For personal use only Name Shares Held % issued shares Ordinary Shares on issue 805.7m Malcolm Pradhan 134.6m 16.7% Share price (15/03/19) 0.048 Ray Blight 95.8m 11.9% BSPE Medical Technology Pty Ltd (Blue Market Capitalisation $38.7m 84.9m 10.5%
Slide 15: Contacts
Contacts For personal use only Kyahn Williamson Head of Investor Communication WE Buchan kwilliamson@we-buchan.com +61 401 018 828 15